Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

PAVmed to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

PAVM

PAVmed to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

PAVmed Inc. (Nasdaq:PAVM), a highly differentiated, multi-product medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 17, 2016, at 2:00 p.m. Eastern Time. Dr. Aklog will provide a corporate overview including recent developments, discuss the company’s innovative business model and review PAVmed’s lead products. The conference is being held at the Westin Grand Central Hotel in New York City.

To access the live webcast of the presentation, please click here.

About PAVmed

PAVmed Inc. (Nasdaq: PAVM, PAVMW) is a highly differentiated, multi-product medical device company employing a unique business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding multi-product pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs, have attractive regulatory pathways and market opportunities and encompass a broad spectrum of clinical areas including carpal tunnel syndrome (CarpX™), medical infusions (NextFlo™ and NextCath™), interventional radiology (PortIO™ and NextCath), tissue ablation and cardiovascular intervention (Caldus™). The Company intends to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. For further information, please visit www.pavmed.com.

For PAVmed Inc.
Investors
LHA
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
Or
Media
Rooney Partners LLC
Kate Barrette, 212-223-0561
Kbarrette@rooneyco.com

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today